Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder [Phase 3]

View source ↗

Summary

Phase 3 study evaluating TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive bladder cancer; the trial is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Cetrelimab
• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urinary Bladder Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING